Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$2.4 - $4.71 $44,640 - $87,606
-18,600 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$20.38 - $34.07 $379,068 - $633,702
18,600 New
18,600 $411,000

About TCR2 THERAPEUTICS INC.


  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Altshuler Shaham LTD Portfolio

Follow Altshuler Shaham LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Altshuler Shaham LTD, based on Form 13F filings with the SEC.

News

Stay updated on Altshuler Shaham LTD with notifications on news.